Candriam S.C.A. Viridian Therapeutics, Inc.\De Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VRDN
# of Institutions
176Shares Held
76.5MCall Options Held
566KPut Options Held
357K-
Black Rock Inc. New York, NY4.77MShares$103 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$95.7 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$84 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$81.2 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$74.6 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $863M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...